Annovis Bio Appoints Andrew Walsh as Vice President Finance
01 Diciembre 2023 - 6:30AM
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform
company developing novel therapies for neurodegenerative diseases
such as Alzheimer’s (AD) and Parkinson’s disease (PD) today
announced the appointment of Andrew Walsh as VP, Finance.
"We remain steadfast in advancing our lead candidate buntanetap,
as we gear up to receive pivotal data from both our Alzheimer’s and
Parkinson’s clinical trials in 2024. The addition of Andrew Walsh
to our team marks another step in our growth plans," said Maria
Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew
brings 12 years of extensive experience in finance operations,
adding a significant layer of strength that will be integral to the
company’s continued success."
"I am thrilled with my new role and the ability to work
alongside Maria and the leadership team to advance Annovis at such
a pivotal time. We will be working collaboratively to position the
Company to achieve its goals," said Mr. Walsh.
Mr. Walsh joins Annovis from Ocugen, a clinical stage
biotechnology company developing novel gene and cell therapies as
well as vaccines, where he most recently served as Senior Director,
Finance and Treasury. Andrew began his career at KPMG in corporate
tax and has since held roles of increasing responsibility at
InVentiv Health, PQ Corporation and Potters Industries. Mr. Walsh
obtained his BS in Accounting from Drexel, graduating summa cum
laude.
About Annovis Bio, Inc.Headquartered in Berwyn,
Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform
company addressing neurodegeneration, such as Alzheimer’s Disease
(AD), Parkinson’s Disease (PD), and other chronic neurodegenerative
diseases. It is believed to be the only company developing a drug
for both AD and PD designed to inhibit more than one neurotoxic
protein to restore axonal and synaptic activity. By improving brain
function, the company’s goal is to treat memory loss and dementia
associated with AD as well as body and brain dysfunction associated
with PD. For more information on Annovis Bio, please visit the
Company's website www.annovisbio.com and follow us on LinkedIn and
Twitter.
Forward-Looking StatementsThis press release
contains "forward-looking" statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. The Company advises caution
in reliance on forward-looking statements. Forward-looking
statements include, without limitation, the Company's plans related
to clinical trials. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results to differ materially from those implied by forward-looking
statements, including regarding patient enrollment, the
effectiveness of Buntanetap and the timing, effectiveness, and
anticipated results of the Company's clinical trials evaluating the
efficacy, safety and tolerability of buntanetap. See also
additional risk factors set forth in the Company's periodic filings
with the SEC, including, but not limited to, those risks and
uncertainties listed in the section entitled "Risk Factors," in the
Company's Annual Report on Form 10-K and Quarterly Reports on Form
10-Q filed with the SEC. All forward-looking statements in this
press release are based on information available to the Company as
of the date of this filing. The Company expressly disclaims any
obligation to update or alter its forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
Investor Contacts:Maria Maccecchini,
Ph.D.maccecchini@annovisbio.com
Annovis Bio (AMEX:ANVS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Annovis Bio (AMEX:ANVS)
Gráfica de Acción Histórica
De May 2023 a May 2024